VJHemOnc Podcast

Explore the use of Calibrutinib in treating blood cancer, the risk of aspergillosis with BTK inhibitors, patient response to acalabrutinib and the importance of CAR T cell therapy, the potential of PUTO Brutonium in previously treated lymphomas, and the results and safety profile of terabritinib in patients with NHL.

Podcast discusses latest updates on T-cell therapies for non-Hodgkin lymphoma, including response rates, remission rates, survival outcomes, and adverse events. Neurotoxicity and toxicity profile of T-cell therapies is analyzed. Phase two Zuma 12 study is compared to Zuma One study. Relationship between molecular response and complete remission explored. Safety profile and effectiveness of third-party EVV cytotoxic T lymphocytes discussed.

Promising results in non-Hodgkin lymphoma treatment using bispecific antibodies, including CD20/CD3. These antibodies have shown encouraging response rates in aggressive and indolent NHL. Case studies highlight complete remission and use as a bridge to CAR T-cell therapy or retreatment. Glofit MAB, a two-to-one format bispecific antibody with high binding affinity to CD20, shows promising response rates. Testing step dosing regimen improves safety and efficacy of CD20/CD3 bispecific antibodies. ODRIN-XDIMAP Phase 1 study reveals potential biomarker associations.

CAR-T therapy for lymphoma discussed, including FDA-approved treatments, progression and toxicity concerns. Factors affecting durability, retreatment outcomes, neurologic toxicity, and outpatient administration explored. Response and safety profile of patients on Transcend trial with prior CD19-directed therapy analyzed. Updates on CAR-T therapy efficacy, safety, and optimization mentioned. Advancements and challenges in CAR-T therapy for lymphoma discussed.

PET scans and risk stratification are being used to improve the treatment of relapsed/refractory Hodgkin lymphoma. Five-year follow-up data from trials of immunotherapy combinations show durable remissions. The use of PET scans in bulky classical Hodgkin lymphoma is discussed. Side effects and fertility issues in Hodgkin lymphoma treatment are also explored.

Speakers discuss latest updates in hematological stem cell transportation, including Italoosa map for graft versus host disease, Glaztege for refractory esclerotic chronic DBSD, and impaired microvascular function in ALO-HCT survivors.

Nina Shah and other experts discuss the use of CAR-T therapy in multiple myeloma, highlighting the impressive results of the CRB-401 study and the significance of deep responses. They also explore the improvements in quality of life with IDESL treatment, challenges related to determining treatment lines, and the approval of the first cell-based gene therapy. The podcast covers the safety, efficacy, and ongoing studies of Sulta Cell and the use of T-cell engaging antibodies for multiple myeloma, including factors to consider when selecting therapy.

Guests including Gilles Salles, Nirav N. Shah, Ulrich Jäger, and Stephen Ansell discuss the latest updates in lymphoma from EHA and ICML 2021, highlighting antibody, cellular, and novel therapies. Topics covered include immune therapies, potential combinations of antibodies, challenges of implementing new therapy in community settings, novel BTK inhibitors, personalized treatment approaches, and advancements in lymphoma research and treatment.

Experts Paolo Ghia, Susan O'Brien, Lydia Scarfò, and Othman Al-Sawaf review exciting updates in chronic lymphocytic leukemia (CLL) from EHA and ICML 2021. They discuss key clinical trials, second-generation BTKs, fixed-duration therapy, depth of response, stopping treatment, retreatment potential, progression-free survival, VTK inhibitors, akylobrutinib vs. britinib, and different CLL treatment regimens.

The podcast discusses updates on treatment for myelodysplastic syndromes (MDS), including the effectiveness of I-Metal Stat in inducing transfusion independence for low-risk patients, the findings of a phase 1 trial investigating a Tim 3 inhibitor for high-risk MDS patients, and the promising efficacy of subotolomab with hypermethylating agents for high-risk MDS. It also provides an update on the phase 2 ISTC GI MDS study examining the effects of CEDIS-TAT on refractory MDS patients.